Two disclosures this week resolve into one pattern, and it is not the pattern either buyer wants investors to see. Unitree’s regulatory filing shows humanoid robots crossing half the company’s revenue for the first time, at a gross margin that held, while the bottom line fell anyway. A parallel investigation into Chinese military procurement shows the next demand story, the one meant to succeed the industrial-deployment story this publication has already priced apart, running the identical first act: heavy documentation of intent to buy sensing and data systems, no confirmed record of an actual deployment. The market is being asked to pay for deployment twice, on two different ledgers, before either one has produced a single fielded unit doing the job it was bought for.
The filing sets the pivot number. Unitree’s response to the Shanghai Stock Exchange’s audit implementation letter, dated May 20 and read against the underlying figures this session, shows humanoid robots reaching 51.78 percent of 2025 revenue, the first year the category has carried the majority of a business long built on quadrupeds. Full-year 2025 revenue came to 1.699 billion yuan on a 60.44 percent gross margin, and R&D spending more than doubled year over year to 144.97 million yuan. None of that explains the first quarter. Non-GAAP net profit fell 52.55 percent year over year in Q1 2026 even as revenue grew 68.49 percent, and the company’s own interim disclosure in August showed the pattern held into the half: revenue up roughly 48 percent, non-GAAP profit still down about 19 percent [figures for the August interim disclosure via company-results reporting, not the raw filing checked this session]. The stock listed on August 19 at a 219 times issue multiple and closed its debut day up 629 percent, a gain that puts a market value near 66 billion dollars behind a business whose cost base is currently growing faster than the higher-margin product line that is supposed to fix it. Core components are more than 90 percent self-developed, per the same filing, which is the strongest argument for why the margin should eventually hold. It is not evidence that it has. The market priced the mix shift as a margin repair. The filing shows the mix shift arriving with a profit decline attached, not instead of one, which is a different and cheaper thing to have bought.
The pattern repeats one layer up. A Reuters investigation published September 7 reviewed more than 100 Chinese military procurement notices, patents, academic papers, and defense-contractor materials on humanoid robots, and found the same evidentiary shape as the industrial story: a National University of Defense Technology tender from June 2025 for an “embodied humanoid robot intelligent perception and dexterous operation system,” a roughly 300,000 dollar contract for a camera-and-radar training-data collection rig, and, at August’s World Robot Conference, defense manufacturer Norinco unveiling a teleoperated humanoid called Fuxi built for sentry, reconnaissance, and patrol roles [Reported: Reuters investigation, September 7; procurement notices themselves not independently checked this session]. What the more than 100 records do not show, per that investigation, is a single confirmed operational deployment. Chinese manufacturers already hold roughly 95 percent of global humanoid shipments, per BofA Global Research, so the hardware capacity to arm this narrative already exists. What does not yet exist is evidence that any of it has moved past a sensor-and-data acquisition phase into a unit actually standing a post. That is the same gap the industrial-deployment story carried before this publication went into the prospectus and found it: procurement volume mistaken for procurement outcome.
The competitive control group is arriving on the same terms. Leju Intelligence, a second humanoid maker, cleared the “already inquired” stage of its ChiNext listing review in late May and is working through the exchange’s questions now. Its reported financials show why the timing matters: revenue near 54 million yuan in 2023, 55.5 million in 2024, and then roughly 258 million in 2025, a near-quintupling in one year, while net losses widened each year and stood at about 71 million yuan in 2025 [Reported: company-profile and press aggregation of the ChiNext filing; not verified against Leju’s own inquiry-response document this session]. Leju is proposing to raise 2.6 billion yuan on a growth curve steeper than Unitree’s and a margin structure that, unlike Unitree’s, has not yet crossed into profitability at all. Tencent and Shenzhen Capital Group sit among its shareholders, which is the same kind of strategic-backer signal that helped set Unitree’s price, and it will invite the same read: growth this fast is treated as evidence of demand rather than as a company still subsidizing its way to scale. If Leju prices anywhere near a comparable multiple, the market is not making one bet on whether humanoid deployment is real. It is making the same bet twice, with two different companies supplying the growth number and neither supplying the deployment number yet.
None of this says the thesis behind either valuation is wrong. Revenue at both companies is real, audited, and growing faster than almost anything else in Chinese hardware. The gap is specifically between the deployment story being sold and the deployment evidence on file, in both the industrial version and now the military one, and gaps of that shape do eventually close in one direction or the other.
What would settle it. Unitree’s third-quarter report, due by China’s standard late-October filing deadline, is the nearer test: the market is pricing in a second-half inflection in the cost ratio, and a quarter that still shows expenses outrunning revenue would mean the margin story, not just the deployment story, needs re-pricing. The farther and larger test is a single confirmed instance, in a company disclosure or an official military record rather than a procurement notice, of a Chinese-made humanoid actually performing an operational role rather than being purchased to learn how to perform one. Either disclosure would move a number this publication is already tracking. Neither has happened yet.
This is research, not investment advice.